Edgewise Therapeutics (EWTX) Change in Accured Expenses (2020 - 2026)

Edgewise Therapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at $635000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 420.49% year-over-year to $635000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 70.27% YoY) and the FY2025 annual result came in at $691000.0, down 40.33% from the prior year.
• Change in Accured Expenses fell to $635000.0 in Q1 2026 per EWTX's latest filing, from $1.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.9 million in Q2 2023 and troughed at -$2.8 million in Q1 2024.
• A 5-year average of $316588.2 and a median of $635000.0 in 2026 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses tumbled 242.96% in 2022, then surged 420.49% in 2026.
• Over 5 years, Change in Accured Expenses stood at $1.3 million in 2022, then slipped by 3.09% to $1.3 million in 2023, then declined by 14.69% to $1.1 million in 2024, then surged by 30.78% to $1.4 million in 2025, then sank by 55.78% to $635000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $635000.0, $1.4 million, and $548000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.